Dr. Duncan on the Expansion of CAR T-Cell Therapy

Video

In Partnership With:

Christine N. Duncan, MD, a senior physician at Dana-Farber Cancer Institute, and assistant professor of pediatrics, Harvard Medical School, discusses the expansion of CAR T-cell therapy in oncology.

Christine N. Duncan, MD, a senior physician at Dana-Farber Cancer Institute, and assistant professor of pediatrics, Harvard Medical School, discusses the expansion of CAR T-cell therapy in oncology.

Since its inception in B-cell acute lymphoblastic leukemia (ALL), it is exciting to see CAR T-cell therapy expand to other malignancies and patient populations, says Duncan. It is also encouraging to see products being developed that target more than CD19, as patients with CD19-targeted disease treated with CD19-directed CAR T-cell therapy ultimately relapse with CD19-negative disease. Now, there are data showing that CAR T cells can be used to target both CD19 and CD22.

Beyond that, there's a population of patients who have relapsed T-cell ALL, who until recently, were unable to receive CAR T-cell therapy, says Duncan. Those patients have a poor survival rate after relapse of approximately 28% or less. It's exciting to see CAR T-cell studies developing and expanding to include very high-risk patient populations. In keeping with the current pace of progress, investigators are hopeful that CAR T-cell therapy will expand to entirely new populations.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD